Murray Mandryk’s Jan 27 column entitled “Saskatchewan’s new drug ... letters to the editor. • Letters should be limited to no more than 250 words. • Include your full name, address ...

The FDA has said it cannot approve tabelecleucel to treat patients 2 years of age and older who have EBV-positive PTLD and have received at least 1 prior therapy.

The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers ...

This article about safe drug supply systems and the problems they ... A more caring society would seek out and address root causes. It would cost more in the short term, but think of what it ...

Write us: We welcome letters up to 150 words, and guest columns of 500-600 words. We reserve the right to edit for clarity and length. Include your name, address and daytime phone number.

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

In general, this is Mexico’s problem, and they have begun to address it by suing two or three of the most egregious gun manufacturers. Good luck with that. My problem with all of this is a ...

The FDA didn't approve the therapy in EBV-positive post-transplant lymphoproliferative disease due to findings at a third-party manufacturing facility.

The warning letter follows an FDA inspection of Hologic’s Marlborough, Massachusetts, headquarters between July 30, 2024, and Sept. 24, 2024. The FDA raised concerns that Biozorb’s device design did ...

Jan. 15 (UPI) --President Joe Biden on Wednesday highlighted the accomplishments of his administration in a White House letter before he is set to issue his farewell address in the evening.

The FDA has issued a complete response letter to the biologics license application seeking ... and the third-party manufacturer to address the feedback to support marketing approval for tabelecleucel, ...